Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
NCT01145352
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients in active polyarticular JIA (restricted to the case of lack of effect by other treatment) during enrollment period (2.5years).
- Patients receiving Enbrel for JIA as diagnosed by a qualified physician.
- Age 5 - 16 years
- Patients not administered ENBREL
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Tokyo,
- Minneapolis, Minnesota
- Minneapolis, Minnesota
- Cincinnati, Ohio
- Portland, Oregon
- Bad Bramstedt,
- Hamburg,
- St. Augustin,
- Krakow,
- Lodz,
- Piestany,
- Westmead, Sydney, New South Wales
- Parkville, Melbourne, Victoria
- Brussels,
- Gent,
- Leuven,
- Barranquilla, Atlantico
- Bogota, Cundinamarca
- Bucaramanga, Santander
- Brno,
- Praha 2,
- Praha 2,
- Le Kremlin Bicetre,
- Paris Cedex 14,
- Paris,
- Berlin,
- Bremen,
- Hamburg,
- Hannover,
- St. Augustin,
- Budapest,
- Chieti,
- Riga,
- Riga,
- Vilnius,
- Mexico City,
- Utrecht,
- Oslo,
- Bydgoszcz,
- Krakow,
- Warszawa,
- Wroclaw,
- Moscow,
- Saint-Petersburg,
- Belgrade,
- Nis,
- Kosice,
- Piestany,
- Ljubljana,
- Esplugues de Llobregat, Barcelona
- Madrid,
- Madrid,
- Valencia,
- Little Rock, Arkansas
- Little Rock, Arkansas
- Loma Linda, California
- Loma Linda, California
- Loma Linda, California
- Loma Linda, California
- Loma Linda, California
- Los Angeles, California
- San Bernardino, California
- San Diego, California
- San Diego, California
- San Diego, California
- San Diego, California
- Hartford, Connecticut
- Hartford, Connecticut
- Washington, District of Columbia
- Washington, District of Columbia
- Miami, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Augusta, Georgia
- Chicago, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Indianapolis, Indiana
- Indianapolis, Indiana
- Boston, Massachusetts
- Minneapolis, Minnesota
- Minneapolis, Minnesota
- Hackensack, New Jersey
- Bronx, New York
- Bronx, New York
- Lake Success, New York
- New Hyde Park, New York
- New York, New York
- New York, New York
- Charlotte, North Carolina
- Charlotte, North Carolina
- Charlotte, North Carolina
- Cincinnati, Ohio
- Portland, Oregon
- Portland, Oregon
- Philadelphia, Pennsylvania
- Austin, Texas
- Austin, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Seattle, Washington
- Westmead, New South Wales
- Parkville, Victoria
- Birmingham, WEST Midlands
- Bristol,
- Bristol,
- Madrid,
- Tolyatti,
- Saint-Petersburg,
- San Luis Potosi,
- Istanbul,
- Curitiba, Parana
- Moscow,
- Vancouver, British Columbia
- Vinnitsya,
- Calgary, Alberta
- Istanbul,
- Juiz de Fora, MG
- Haifa,
- San Luis Potosi,
- San Miguel de Tucuman, Tucuman
- Sao Paulo,
- Moscow,
- Montreal, Quebec
- Vancouver, British Columbia
- Kayseri,
- Ankara,
- Caba,
- Calgary, Alberta
- Bydgoszcz,
- San Luis Potosi,
- Kfar Saba,
- Rosario, Santa FE
- Istanbul,
- Guadalajara, Jalisco
- Valencia,
- Ivano-Frankivsk,
- Leuven,
- Salvador, Bahia
- Ramat Gan,
- Sao Paulo, SAN Paulo
- Moscow,
- San Luis Potosi,
- Montreal, Quebec
- Curitiba, Parana
- Botucatu, SAO Paulo
- Minneapolis, Minnesota
- Rio de Janeiro, RJ
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance] | |||
Official Title | Enbrel-JIA Use Results Survey [All-Case Surveillance] | |||
Brief Summary | This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA.
| |||
Detailed Description | All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year). | |||
Study Type | Observational | |||
Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Probability Sample | |||
Study Population | All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year). | |||
Condition | Juvenile Idiopathic Arthritis | |||
Intervention | Drug: Etanercept (genetical recombination)
All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year). Other Name: Enbrel | |||
Study Groups/Cohorts | Etanercept (genetical recombination)
All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year). Intervention: Drug: Etanercept (genetical recombination) | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment | 113 | |||
Original Estimated Enrollment | 300 | |||
Actual Study Completion Date | October 2013 | |||
Actual Primary Completion Date | October 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | 5 Years to 16 Years (Child) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT01145352 | |||
Other Study ID Numbers | 0881Y1-4689 B1801130 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor | Pfizer | |||
Collaborators | Not Provided | |||
Investigators |
| |||
PRS Account | Pfizer | |||
Verification Date | August 2014 |